LSD1-IN-27

• UNSPSC Description:

  LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer[1].

• Target Antigen:

  Histone Demethylase; PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-27.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=CC=C2C(C(NC3=CC=C(N(C)C)C=C3)=C4C(C(C)=C(C)C=C4)=N2)=C1

• Molecular Weight:

  355.48

• References & Citations:

  [1]Dai XJ, et al. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. Eur J Med Chem. 2023 Nov 5;259:115684.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2904571-94-2